fingolimod hydrochloride has been researched along with Fatty Liver, Nonalcoholic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Asgharpour, A; Bedossa, P; Cowart, LA; Maczis, MA; Montefusco, D; Rohrbach, TD; Sanyal, AJ; Spiegel, S | 1 |
| Hirsova, P; Maiers, JL; Malhi, H; Mauer, AS; Shah, VH | 1 |
2 other study(ies) available for fingolimod hydrochloride and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
FTY720/fingolimod decreases hepatic steatosis and expression of fatty acid synthase in diet-induced nonalcoholic fatty liver disease in mice.
Topics: Acetylation; Animals; Diet, High-Fat; Fatty Acid Synthases; Female; Fingolimod Hydrochloride; Immunoblotting; Insulin Resistance; Liver; Lysophospholipids; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Organophosphates; Sphingolipids; Sphingosine; Triglycerides | 2019 |
Inhibition of sphingosine 1-phosphate signaling ameliorates murine nonalcoholic steatohepatitis.
Topics: Animals; Diet, High-Fat; Disease Models, Animal; Fingolimod Hydrochloride; Hepatocytes; Hepatomegaly; Liver; Male; Mice; Non-alcoholic Fatty Liver Disease; Receptors, Lysosphingolipid; Signal Transduction; Triglycerides | 2017 |